The engineered CAR-NK cells mitigated clinical symptoms and reduced tumor burden in metastatic cancer sites24; however, the clinical efficacy of NKG2D-DAP10-CD3ζ NK cells on hematologic malignancies needs to be determined. The gene discussed is KLRK1; the disease is neoplasm.